Concomitant complementary medicine (CM) and conventional medicine use is frequent and carries potential risks. Yet, CM users frequently neglect to disclose CM use to medical providers. our systematic review examines rates of and reasons for CM use disclosure to medical providers. observational studies published 2003-2016 were searched (AMED, CINAHL, MEDLINE, PsycINFO). Eighty-six papers reporting disclosure rates and/or reasons for disclosure/non-disclosure of CM use to medical providers were reviewed. Fourteen were selected for meta-analysis of disclosure rates of biologically-based CM. Overall disclosure rates varied (7-80%). Meta-analysis revealed a 33% disclosure rate (95%CI: 24% to 43%) for biologically-based CM. Reasons for non-disclosure included lack of inquiry from medical providers, fear of provider disapproval, perception of disclosure as unimportant, belief providers lacked CM knowledge, lacking time, and belief CM was safe. Reasons for disclosure included inquiry from medical providers, belief providers would support CM use, belief disclosure was important for safety, and belief providers would give advice about CM. Disclosure appears to be influenced by the nature of patient-provider communication. However, inconsistent definitions of CM and lack of a standard measure for disclosure created substantial heterogeneity between studies. Disclosure of CM use to medical providers must be encouraged for safe, effective patient care.
Health care seeking invariably involves choices regarding the use of what can often be many competing health care services, treatments and providers from both within and beyond the public health care system. This level of individual choice in health seeking is increasingly recognised with person-centred care being given predilection as a favourable model of care provision in public health 1, 2 , situating individuals as active participants at the centre of their health management. Patient autonomy and preference are important features of person-centred care 2 to be considered by medical providers alongside safety and treatment outcomes in their patient management.
Amidst this context, complementary medicine (CM) -a broad, varied field of health care practices and products customarily excluded from conventional medical practice and dominant health care systems 3 -is often the focus of relatively hidden patient health seeking yet is making its presence felt in primary care, chronic disease management and other areas 4 . Despite appreciable gaps in evidence of effectiveness 5 , CM use remains prevalent amongst the general population 6 . While there is controversy amongst medical providers around the role and value of CM 7 , the vast majority of CM use is concurrent to conventional medicine 8 with CM users visiting a GP more frequently than non-CM users 9 .
Serious adverse effects and harm from CM appear relatively rare but substantial associated direct and indirect risks remain 10, 11 , particularly regarding ingestive biologically-based CM (such as herbal medicines or supplements) [12] [13] [14] , which may be obtained from unreliable sources, self-prescribed or consumed without professional supervision 11, 15 . Exacerbating such risks is an absence of both awareness of concurrent CM and conventional medicine use, and of procedures ensuring appropriate oversight of concurrent use 11 . Furthermore, patients often approach CM as inherently safe and may not perceive a need to communicate their CM use to medical providers 16, 17 . Addressing the risks associated with concurrent use is the responsibility of both patients and their medical providers 18 , and arguably essential for general practitioners in their capacity as primary care gatekeepers 19 .
A previous review of the literature pertaining to CM use disclosure to medical providers published in 2004 identified twelve papers published between 1997-2002 reporting a CM disclosure rate of 23-90% alongside key factors -patient concern about possible negative response from their medical provider, patient perception that selection criteria. Our review included cross-sectional data from observational studies as this research design was deemed the most appropriate for determining prevalence of health behaviours, determinants and outcomes 27 . All observational study designs constituting original, peer-reviewed research were considered for the qualitative synthesis if they reported on rates of, or reasons for, disclosure/non-disclosure of CM use to conventional medicine providers by a broad range of members from the general population. CM use was defined as the use of any practice or product falling outside of those considered part of conventional medicine 28 , whether administered as self-treatment or by a CM practitioner. We excluded experimental study designs, which may have impacted on natural communication patterns between patients and providers, alongside studies assessing specific populations which could not reasonably be considered to represent a broad range of individuals (e.g. disease-specific populations). Studies were not excluded on the basis of language.
During selection of studies for meta-analysis, additional criteria were applied with respect to homogeneity, in order to ensure the central estimate of disclosure frequency would provide external validity. This additional criteria required that participants were adults, the study reported a true and well-defined rate of disclosure occurring within the previous twelve months, and involved participants who used biologically-based CM (herbs/ plant-based medicines, vitamins, minerals and other oral supplements). Of those papers reporting studies sharing a common data source (e.g. if multiple papers reported on data from the same survey study), we included only one of those publications in order not to artificially inflate our sample size. In such cases, the risk of bias was evaluated for all such publications and only included that publication deemed to have the lowest risk of bias. study selection. Citations were exported into EndNote X8 (Clarivate Analytics 2017) reference management software for assessment. Following removal of duplicates, the initial citations were screened against inclusion/exclusion criteria by title and abstract. Review and commentary articles were set aside for a manual search of their included studies. Remaining citations were screened by full-text perusal and those found to adhere to all selection criteria were selected for review. The reference lists of the selected studies were manually searched for Scientific RepoRts | (2019) 9:1573 | https://doi.org/10.1038/s41598-018-38279-8 additional articles. Full review of all eligible citations was conducted by the lead author (HF). A selected sample of eligible studies (10%) were reviewed at each stage of screening by a second reviewer (AS), as were any studies under question, and discrepancies were addressed through discussion until consensus was reached. The justification for excluding articles following screening the full text was recorded.
Data extraction and risk of bias assessment. Papers selected for review were re-read thoroughly with data extracted into pre-prepared tables outlining study characteristics, outcomes of interest (disclosure/ non-disclosure rates and reasons) and parameters of those outcomes (CM type disclosed, how disclosure was defined). Further to this, papers were read in full-text once more to identify other notable findings relating to disclosure, which were categorised and tabulated heuristically. The template for data extraction was drafted during the pre-review protocol development phase with agreement from all authors. Data extraction was conducted by one reviewer (HF) with a selected sample (10% alongside any data under question) checked by another reviewer (AS). Any discrepancies were addressed through discussion until consensus was reached. The resulting tables were examined to identify studies meeting the criteria for meta-analysis. These identified studies were subjected to risk of bias assessment using Hoy et al. 's tool for prevalence studies, which assesses ten items across four domains (sample selection, non-response bias, measurement bias, analysis bias) alongside a summary score 29 . Studies identified as high risk of bias were excluded from the final selection for meta-analysis. Risk of bias was considered high if four or more items were not adequately addressed, if the first three items indicated an unacceptable level of sampling bias, or if item ten was not adequately addressed as this item affected calculation of disclosure rates.
Data synthesis and statistical analysis.
Due to the expected heterogeneity of each study's parameters of disclosure, no average disclosure rate was calculated for the full review; instead a meta-analysis was conducted on those studies demonstrating sufficient homogeneity in study design and a low risk of bias. The principal summary measure used for meta-analysis was disclosure rate of CM use to medical providers. Meta-analysis was conducted using events (number of disclosers) and subset of sample size (number of CM users) to determine event rates of disclosure. Where studies reported disclosure rates only as percentages, events were calculated using figures for the number of participants who responded to the disclosure question. Where these figures were unavailable, the study was considered to fail to address item 10 on the risk of bias assessment tool and was excluded from meta-analysis.
Statistical heterogeneity between studies was explored using I 2 and chi-square statistics. I 2 values greater than 25%, greater than 50%, and greater than 75% indicate moderate, substantial, and considerable heterogeneity, respectively 30 . Due to the relatively low power of this test, a P value of 0.10 or less from the chi-square test was regarded to indicate significant heterogeneity 30 . Analysis was completed using Comprehensive Meta-Analysis V3 software (Biostat Inc. 2017).
Results
From an initial 5,071 non-duplicate citations, eighty-six studies were selected for review. The reasons for exclusion at full-text screening are provided in Table 2 .
Risk of bias assessment. Twenty studies met the initial inclusion criteria for meta-analysis and were subjected to assessment of reporting quality and risk of bias using Hoy et al.'s tool for prevalence studies 29 . Collectively, studies performed poorly across most domains relating to external validity, either due to poor methodological conduct or inadequate reporting on methods relating to target population (item 1), random selection (item 3) and response bias (item 4). However, sampling frame representation was well conducted and reported (item 2). Domains relating to internal validity were addressed well, with the exception of instrument validity (item 7).
Of the twenty studies, four were found to exhibit a high risk of bias due to poorly defined parameters for disclosure rate definition or analysis [31] [32] [33] [34] and were consequently excluded from meta-analysis. The remaining sixty-six studies which did not meet the initial inclusion criteria for meta-analysis represented a heterogeneous range of study designs in which disclosure was not reported as a primary outcome, but as a secondary outcome or qualitative finding, and thus the resulting data underwent narrative synthesis without risk of bias appraisal. study characteristics. Of the eighty-six studies reviewed, seventy-nine provided quantitative data [31] [32] [33] , three qualitative data [111] [112] [113] , and four mixed-method data 34, [114] [115] [116] relevant to CM disclosure rates and/or reasons for disclosure/non-disclosure (selection process summarised in Fig. 1 ). Nine studies were excluded following review of the full text. A vast majority of the selected studies (n = 83) used a cross-sectional survey design 31, 32, [114] [115] [116] , two employed a multistage qualitative approach 111, 112 , and one an ethnographic interview design 113 44, 113 , seminars 78, 80 , and online platforms 32, 83 . While some samples consisted entirely of CM users 45, 50, 51, 54, 83, 89, 98 , most involved a subset of CM users within a larger sample. Full samples ranged from 35 to 34,525 with an average of 4,144. Amongst those studies reporting figures for the subset of CM users, samples ranged from 28 to 16,784 with an average of 1,268 and a total of 101,417. Participants were predominantly adults with a small number of studies focussed on older adults 44, 57, 65, 94, 95, 105, 110, 113, 114 , children 45, 58, 63, 68, 73, 97, 103, 106, 115, 116 , adolescents 41, 97 , or all age groups 61, 99, 112 . More than half of the studies included users of various types of CM (n = 45) 31, 35, 36, 38, [41] [42] [43] 50, 51, 54, [57] [58] [59] [61] [62] [63] 65, 66, 68, 72, 73, 75, 76, [80] [81] [82] 85, 88, 89, 96, 97, [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] 115, 116 , while others were limited to users of specific types of CM such as herbs and/or supplements [32] [33] [34] 37, [44] [45] [46] [47] 52, 53, 55, 56, 60, 64, 67, [69] [70] [71] 74, [77] [78] [79] 83, 86, 87, [92] [93] [94] [95] [98] [99] [100] [101] 109, 114 , yoga 48, 91 , tai chi 49, 90 , mind-body medicine 40 , practitioner-provided CM 39 , or local traditional medicine 84 .
A l m o s t h a l f of t h e s e l e c t e d s tu d i e s ( n = 4 0 ) u s e d a c onv e n i e n c e s a mp l i n g m e t hod 32, [34] [35] [36] [37] [41] [42] [43] [44] 55, 58, [60] [61] [62] [63] [64] 66, 68, 69, 74, [76] [77] [78] [79] [80] [81] [82] 86, 87, 92, 97, 101, 103, 106, 107, 109, 111, [114] [115] [116] . However, twenty-two studies used a nationally representative sample 31, 39, 40, [46] [47] [48] [49] [50] [51] [52] [53] [54] 59, 73, 85, [89] [90] [91] 94, 96, 100, 110 , while others applied some method of probability randomisation 38, 56, 65, 75, 84, 88, 99 , stratification 33, 45, 57, 67, 70, 72, 93, 108 , weighting 71, 104, 113 , or purposiveness 95, 98, 102, 105, 112 during sampling. Table 4 provides full details of the study characteristics identified from the reviewed literature.
Following risk of bias assessment, sixteen studies were considered suitable for meta-analysis of CM disclosure rates. Two were excluded from analysis 46,52 on the basis that they used data from an earlier version of the same national survey as reported in another included manuscript 54 prevalence and parameters of disclosure. Rates of disclosure varied substantially across studies, ranging from 7% 114 to 80% 40 . Studies including biologically-based CM fell within a range of 7% 114 to 77% 44 , while the highest rate of disclosure (80%) was reported by researchers assessing the use of mind-body medicine exclusively 40 . Parameters used for defining and measuring disclosure also varied, with the most common parameters outlined as participant disclosure of their use of CM within the last twelve months to a medical provider (n = 30) [31] [32] [33] 36, 38, 40, [45] [46] [47] [48] [49] [50] 52, 54, 57, 62, 65, 67, 68, 70, 71, 73, 81, 82, 84, 85, 87, 88, 95, 100, 115, 116 . Others studies examined participants' disclosure to a medical provider of their current CM use 35, 74, [77] [78] [79] 83, 98, 109, 111 , use within the last month 34, 53, 69, 86 , use within the last 24 months 50,51 , had always/usually/sometimes/never disclosed 39, 59, 60, 66, 72, 110 , had ever discussed their CM use with a conventional provider 37, 43, 64, 75, 76 , had partially or fully disclosed their CM use 56, 114 , had disclosed when asked 41 , had discussed before use 92 , reported rates of disclosure per episode of use 89 , or how the patient felt about disclosing 80, 112 . A number of papers did not explicitly define their parameters for measuring disclosure 42 The outcomes of the meta-analysis of the rate of disclosure of CM use by individuals using biologically-based CM is presented in Fig. 2 . The measure of central tendency provided an overall disclosure rate of 33% (95% CI 24·1% to 42·8%, I 2 = 98·6%). Between the fourteen included studies, the lowest reported disclosure rate was 12% and the highest was 59%. Heterogeneity was assessed across the fourteen samples (Q-value 904.955, p < 0.001, I 2 = 98.563). Although homogeneity was affected by the substantially larger sample size in Jou et al. 's 2016 study 54 , the paper was not excluded as it used a strong, internationally recognised dataset with very low risk of bias. The employment of a random effects model accounted for the impact of this study on homogeneity and its inclusion was not found to impact significantly on the measure of consistency within this model. Table 3 . Risk of bias assessment for meta-analysis selection (selected papers in bold). N = criterion not adequately met; Y = criterion adequately met. Reasons for non-disclosure and disclosure. Twenty-five studies reported participant reasons for non-disclosure 36, 37, 42, [54] [55] [56] [57] 59, 67, [76] [77] [78] [79] [83] [84] [85] 90, 92, 98, 105, 107, [110] [111] [112] [113] , and four reported reasons for disclosure of CM use to medical providers 56, [111] [112] [113] . The most commonly cited reasons patients gave for non-disclosure were fear of the provider's disapproval 36 36, 42, 54, 56, 57, 76, 78, 92, 105 , belief that CM was safe and would not interfere with conventional treatment 42, 78, 83, 85, 111 , the patient not using CM regularly or at the time of consulting with the conventional provider 54, 78, 83, 85 , and previous experiences of a negative response from conventional providers 54, 84, 90, 112 . The most commonly cited reason for disclosure was that the provider asked about CM use 56, 111, 112 , followed by the patient expecting the provider to be supportive of their CM use 112, 113 , believing disclosure was important for safety 56, 113 , belief the provider would have relevant knowledge or advice about CM 56 , and belief that disclosing CM use may help other patients with the same condition 56 . Full details of reasons are shown in Table 5 . When participants were asked whether they thought disclosure was important, more than 67% agreed it was 36, 63, 68, 80, 110 . This percentage was highest (93%) among participants who were surveyed in CM clinics 68 , which was consistent with other studies reporting higher disclosure rates among users of practitioner-provided CM compared with self-administered CM 50, 51, 81, 89 . Conversely, one study found lower disclosure rates among those using practitioner-provided CM, specifically where participants were consulting a CM practitioner and a medical provider for the same condition 65 .
Impact of provider response on decisions to disclose. In a qualitative analysis, Shelley et al. found patients' perceptions of how their medical provider might respond to their CM use was an important factor in the decision of whether or not to disclose 112 . A perception of the medical provider as accepting and non-judgemental encouraged disclosure while fear of a negative response from their medical provider led to non-disclosure 112 . One paper reported 59% of participants wanted to discuss CM with their medical provider (despite only 49% having done so), and 37% of non-disclosers wished it were easier to have such discussions 35 . In another study, the percentage of participants who wanted to discuss CM with their provider represented a substantial majority at 82% (despite only 60% having done so) 61 .
When the actual response of the provider to disclosure of CM use was explored by researchers, negative or discouraging responses were reported by a minority of respondents representing less than 20% of disclosers 65, 71, 77, 85, 105 , or were not reported at all 111 . However, in five papers positive or encouraging responses to disclosure of CM use by a medical doctor were reported by a substantial proportion of respondents representing 32-91% of disclosers 63, 65, 77, 79, 85, 105 . Neutral responses from medical providers were also common, reported by 8-32% of disclosers in three studies 77, 85, 111 .
Discussion
This review and meta-analysis provides a detailed overview and update of CM use disclosure to medical providers. Regarding the update to the 2004 paper 20 afforded by this review, a substantially larger volume of literature reporting on CM disclosure was identified in our search, suggesting an increase in researcher interest in this aspect of patient-provider communication. Our analysis reveals little discernible improvement to disclosure rates over the last thirteen years. Consistent with the findings of the previous review, we found reports of disclosure vary widely. However, our additional meta-analysis on selected papers shows approximately two in three CM users do not disclose their CM use to medical providers. In view of the potential risks associated with unmanaged concomitant use of conventional and complementary medicine 11, 14 , the value of increasing this rate of disclosure is accentuated.
Furthermore, our narrative review identified three distinct yet interrelated findings relating to patient-practitioner communication. Firstly, disclosure of CM use to medical providers is influenced by the nature of providers' communication style; secondly, perceived provider knowledge of CM use is a barrier to discussions of CM use in clinical consultation; and thirdly, such discussions and subsequent disclosure of CM use may be facilitated by direct inquiry about CM use by providers. We consider this in the context of contemporary person-centred health care models.
Communication style was a repeated factor affecting disclosure rates in this review; disclosure of CM use was found to be encouraged by patient perceptions of acceptance and non-judgement from medical providers 112 , and inhibited by patient fears or previous experiences of discouraging responses from providers 36, 42, [54] [55] [56] 67, [76] [77] [78] [83] [84] [85] 90, 92, 105, 107, [110] [111] [112] [113] . In practice, negative responses from medical providers appear to represent a deviation from the more commonly positive or neutral responses noted by participants of the reviewed studies as well as others 117, 118 . However, such fears and subsequent non-disclosure of CM use could potentially be addressed by medical providers through communication with patients about CM in a direct, supportive, non-judgemental manner to build trust and communicative success 119 .
The reviewed literature shows patient perceptions of medical providers as lacking relevant knowledge about CM is a notable reason for non-disclosure. While examination of provider attitudes was not within the scope of this review, three reviewed papers included an assessment of medical providers' attitudes toward discussing CM and identified lack of CM knowledge as a cause of providers' reluctance to initiate such discussions 76, 111, 112 . Providers' own perceived lack of CM knowledge as an obstacle to patient-provider CM communication also reflects other research examining provider perspectives on CM 120, 121 . While the inclusion of CM in medical school curricula does occur in some countries (e.g. the US 122 , Canada 123 , UK 124 , Germany 125 , and Switzerland 126 ), and is of interest to medical students 127, 128 , this level of CM learning appears insufficient to equip medical providers with the confidence to address patient CM queries 120, 121 . Furthermore, the depth and scope of CM knowledge to be realistically encouraged amongst medical providers has been contested 124, 125 and may be best facilitated on a case by case basis taking into account the circumstances of both provider and patient involved. Ideally, regardless of the level of CM knowledge held, the medical provider should strive to facilitate overall coordination and continuity of care for patients covering all treatments and providers, including those of CM. Our analyses suggest there may be a vital role for medical providers in facilitating patient preference by enquiring with patients about CM in order to help improve disclosure rates. Other studies show discussions in conventional medical settings about CM use are more commonly patient rather than provider initiated 118, 129 , a pattern reflected in the findings of some papers in this review 35, 68, 76 . This pattern suggests provider initiation of such discussions may be an avenue for improving disclosure rates, which may be achieved by means such as standard inclusion of CM use inquiry in case-taking education for medical students, as is currently the case in Switzerland 130 . Indeed, examination of the impact on disclosure rates of specific questions related to dietary supplements found medical providers' questioning more than doubled the rate of supplement use disclosure 131 . This communicative success may be facilitated through employment of person-centred approaches to clinical care, which encompass patient involvement in shared decision-making, provider empathy and recognition of patients' values 119 , encouraging a shared responsibility for communication and subsequent discussion of CM use.
While this review provides insight which could be integral to improving patient care during concomitant use of CM and conventional medicine, it also reveals the complexities of patient-practitioner communication in contemporary clinical settings. Further research into the nature of prevailing communication patterns, including differences in disclosure behaviours between populations of different demographics, is needed. As research into disclosure becomes more nuanced and data collection more consistent (e.g. through development and use of standardised instruments), future research could examine changes in patterns of and influences on disclosure. Additionally, research exploring the relationship between communication and treatment outcomes is warranted to provide a richer, deeper understanding of the impact of patient care dynamics. Such understanding could arguably provide the scaffolding for robust, effective, efficient public health policy and practice guidelines.
Limitations of this review. The findings from our review need to be considered within the context of certain limitations. The varied nature and lack of a consistent international definition of CM lend a high degree of heterogeneity to the collection of studies appraised 132 . Likewise, while the wide variation in disclosure rates is likely to be partially due to confounding factors relating to differences among target populations (e.g. age, gender), settings (e.g. hospital, community clinics), geographical location (e.g. country/region), and sample sizes, the absence of a standard, validated tool for measuring disclosure also impacts the analysis and reporting on disclosure rates. The heterogeneity produced by these limitations reduced the number of papers suitable for meta-analysis and prevented a more robust, fixed-model meta-analysis on this topic, as well as prohibiting meta-analyses of CM categories other than biologically-based CM due to insufficient data. Additionally, identifying a comprehensive selection of studies to review was difficult due to disclosure frequently being reported as a secondary outcome and thus not being mentioned in the paper's title, abstract or keywords. However, these limitations have been minimised where possible by following systematic review best practice, and while remaining mindful of the limitations of our review, the importance of the findings presented here for contemporary healthcare practice and provision should not be underestimated. 
Conclusion
The rate of disclosure regarding CM use to medical providers remains low and it appears that disclosure is still a major challenge facing health care providers. This review, alongside previous research, suggests that patient decision-making regarding disclosure and non-disclosure of CM use to a medical provider is impacted by the nature of patient-provider communication during consultation and perceptions of provider knowledge of CM. The initiation of conversations about CM with patients and provision of consultations characterised by person-centred, collaborative communication by medical providers may contribute towards increased disclosure rates and mitigate against the potential direct and indirect risks of un-coordinated concurrent CM and Figure 2 . Meta-analysis results: disclosure rates for biologically-based complementary medicine. Results of meta-analysis assessing rates of disclosure of biologically-based complementary medicine use to medical providers.
No. of studies
Studies reporting reason
Studies reporting as main reason a

Reasons for non-disclosure
Patient was afraid of physician's response or thought physician will disapprove 20 36 Didn't think physician had relevant knowledge/wasn't their business to know 10 36,42,54,56,67,76-78,107,113 36 No time/physician too busy/didn't think about it/forgot 9 36,42,54,56,57,76,78,92,105 42 Thought CM was safe/wouldn't interfere with treatment 4 78,83,85,111 83 Was not using CM at the time/not using CM regularly/not attending a physician at the time 4 54,78,83,85 85 Previous negative response or bad experience with disclosing 4 54, 84, 90, 112 Patient had enough knowledge about CM 1 42 Wanted to compare advice between conventional and CM practitioners 1 113 Desire to protect cultural knowledge about CM 1 113 Concerns physician will see patient's CM use as detracting from their income 1 113 
Reasons for disclosure
Physician asked 3 56, 111, 112 Patient believed physician would be supportive 2 112, 113 Patient believed it was important for safety reasons 2 56,113 56 Patient believed physician would have relevant knowledge or advice about CM 1 56 To help someone else with the same condition 1 56 Table 5 . Reasons for non-disclosure and disclosure. a Studies in which the corresponding reason was the reason most commonly reported by participants.
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conventional medical care. This is a topic which should be treated with gravity; it is central to wider patient management and care in contemporary clinical settings, particularly for primary care providers acting as gatekeeper in their patients' care.
